Subscribe to our Newsletters !!
Few developments in science and technology have be
Worldwide, millions of workers handle chemicals us
A new COVID-19 variant, BA.3.2, informally called
Alembic Pharmaceutica
Generic medicines have become a cornerstone in hea
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to the latest issue of Mi
Drug firm Alembic Pharmaceuticals on Monday said it has received establishment inspection report (EIR) from the US health regulator for its new injectable facility at Karakhadi in Gujarat.
The company has, ”received EIR from US Food and Drug Administration (USFDA) for the inspection carried out by them at our new injectable facility at Karakhadi during the period from January 28, 2021 to February 6, 2021, indicating that the USFDA finds our responses to their observations to be adequate,” Alembic Pharmaceuticals said in a regulatory filing.
The US regulator has also indicated that a compliance verification would be performed during re-inspection of the said facility in the next review cycle, it added.
Shares of Alembic Pharmaceuticals closed at Rs 819.45 per scrip on BSE, up 5.42 per cent from its previous close.